ArticleNPJ precision oncology2025

Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.

Xuanjun Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.